

*AB*  
*Sub R3*

12. The method of claim 3 wherein said pathogenic Mycoplasma bacteria is a member of the genus *Mycoplasma*.

13. The method of claim 12 wherein said bacteria is selected from the group consisting of: *Mycoplasma hominis* and *Mycoplasma fermentans*.

14. The method of claim 12 wherein said bacteria is selected from the group consisting of: *Mycoplasma pneumoniae*, *Mycoplasma genitalium*, and *Mycoplasma penetrans*.

15. The method of claim 3 wherein said bacteria is a member of the genus *Ureaplasma*.

16. The method of claim 15 wherein said bacteria is *Ureaplasma urealyticum*.

17. The method according to claim 3 wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.

18. The method according to claim 17 wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.

19. The method according to claim 18 wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.

20. The method according to claim 12 wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.

21. The method according to claim 20 wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.

22. The method according to claim 21 wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.

23. The method according to claim 13 wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.

24. The method according to claim 23 wherein the gemifloxacin compound is gemifloxacin mesylate or a hydrate thereof.

25. The method according to claim 24 wherein the gemifloxacin compound is gemifloxacin mesylate sesquihydrate.

26. The method according to claim 14 wherein the gemifloxacin compound is gemifloxacin or a pharmaceutically acceptable salt thereof.